BioSpace News Archive

Aerovate Therapeutics, Inc. presents Phase 1 results at the American Thoracic Society International Conference in San Francisco.

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of an underwritten public offering of 625,000 American Depositary Shares at a public offering price of $4.00 per ADS.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, has filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws.

ASC Therapeutics in partnership with the University of Massachusetts Medical School and the Clinic for Special Children, will present safety and efficacy results of a dual-function gene replacement vector therapy in murine and bovine models of classic Maple Syrup Urine Disease as a podium presentation on Tuesday, May 17 at the 25th Annual Meeting of The American Society of Gene and Cell Therapy held May 16-19, 2022 in Washington D.C.

Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ended March 31, 2022.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, reported financial results for the first quarter ended March 31, 2022.

La Jolla Pharmaceutical Company announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022.

Gilead Sciences, Inc. announced the U.S. Food and Drug Administration has lifted the clinical hold placed on the company’s Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis.